MedTrace Logo

Phase I to Test a New Pneumococcal Vaccine

NCT03303976 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2018-12-04

No results posted yet for this study

Summary

To obtain first-in-human data on a new candidate vaccine against Streptococcus pneumoniae in healthy adult and elderly volunteers.

The study aims to assess the safety and immunogenicity of a bioconjugate investigational vaccine compared to the control group (Pneumovax23).

Conditions

  • Pneumococcal Pneumonia
  • Pneumonia, Bacterial

Interventions

BIOLOGICAL

Bioconjugate pneumococcal vaccine

Bioconjuagte vaccine against bacterial pneumococcal infection

BIOLOGICAL

Multivalent plain polysaccharide vaccine

Multivalent plain polysaccharide vaccine against bacterial pneumococcal infection

Sponsors & Collaborators

  • LimmaTech Biologics AG

    lead INDUSTRY

Principal Investigators

  • Michael Leidig, MD · CRS Mönchengladbach

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-07
Primary Completion
2018-09-12
Completion
2018-09-12

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03303976 on ClinicalTrials.gov